US20190336739A1 - Systems and methods of stimulation and activation of fluids for use with instillation therapy - Google Patents
Systems and methods of stimulation and activation of fluids for use with instillation therapy Download PDFInfo
- Publication number
- US20190336739A1 US20190336739A1 US16/517,788 US201916517788A US2019336739A1 US 20190336739 A1 US20190336739 A1 US 20190336739A1 US 201916517788 A US201916517788 A US 201916517788A US 2019336739 A1 US2019336739 A1 US 2019336739A1
- Authority
- US
- United States
- Prior art keywords
- fluid
- wound
- energy
- energy source
- wound dressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000012530 fluid Substances 0.000 title claims abstract description 134
- 238000000034 method Methods 0.000 title claims abstract description 22
- 238000002560 therapeutic procedure Methods 0.000 title description 7
- 230000004913 activation Effects 0.000 title description 3
- 230000000638 stimulation Effects 0.000 title description 3
- 230000003213 activating effect Effects 0.000 claims abstract description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 30
- 239000011253 protective coating Substances 0.000 claims description 29
- 238000003860 storage Methods 0.000 claims description 24
- 239000011248 coating agent Substances 0.000 claims description 11
- 238000000576 coating method Methods 0.000 claims description 11
- 230000003115 biocidal effect Effects 0.000 claims description 8
- 238000001804 debridement Methods 0.000 claims description 5
- 230000005865 ionizing radiation Effects 0.000 claims description 5
- 230000000202 analgesic effect Effects 0.000 claims description 4
- 230000000593 degrading effect Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 238000005086 pumping Methods 0.000 claims 1
- 206010052428 Wound Diseases 0.000 abstract description 123
- 208000027418 Wounds and injury Diseases 0.000 abstract description 123
- 230000004936 stimulating effect Effects 0.000 abstract description 2
- 239000013543 active substance Substances 0.000 description 15
- 230000008878 coupling Effects 0.000 description 13
- 238000010168 coupling process Methods 0.000 description 13
- 238000005859 coupling reaction Methods 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 10
- 206010053567 Coagulopathies Diseases 0.000 description 9
- 230000035602 clotting Effects 0.000 description 9
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000004891 communication Methods 0.000 description 5
- 229920001247 Reticulated foam Polymers 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 4
- -1 polypropylenes Polymers 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- 239000004599 antimicrobial Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 238000009581 negative-pressure wound therapy Methods 0.000 description 3
- 229920000747 poly(lactic acid) Polymers 0.000 description 3
- 229920000181 Ethylene propylene rubber Polymers 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 244000043261 Hevea brasiliensis Species 0.000 description 2
- 229920002518 Polyallylamine hydrochloride Polymers 0.000 description 2
- 229920002614 Polyether block amide Polymers 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229920003052 natural elastomer Polymers 0.000 description 2
- 229920001194 natural rubber Polymers 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920002037 poly(vinyl butyral) polymer Polymers 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 239000004632 polycaprolactone Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- MAGFQRLKWCCTQJ-UHFFFAOYSA-M 4-ethenylbenzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=C(C=C)C=C1 MAGFQRLKWCCTQJ-UHFFFAOYSA-M 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- NXELBVYGGDFXOC-LSJACRKWSA-N Cl.C(N)(=N)C1(CC(=C(/C(=C(/C(=O)O)C)/C2=CC=CC=C2)C=C1)O)N(CC)CC Chemical compound Cl.C(N)(=N)C1(CC(=C(/C(=C(/C(=O)O)C)/C2=CC=CC=C2)C=C1)O)N(CC)CC NXELBVYGGDFXOC-LSJACRKWSA-N 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229920006397 acrylic thermoplastic Polymers 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- BLAJPPMSXMTCLR-UHFFFAOYSA-N but-1-ene styrene Chemical compound CCC=C.C=CC1=CC=CC=C1.C=CC1=CC=CC=C1 BLAJPPMSXMTCLR-UHFFFAOYSA-N 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000005465 channeling Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- CQZCVYWWRJDZBO-UHFFFAOYSA-N diphenyliodanium;nitrate Chemical compound [O-][N+]([O-])=O.C=1C=CC=CC=1[I+]C1=CC=CC=C1 CQZCVYWWRJDZBO-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 108010001073 oxyhemoglobin oxidase Proteins 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000019935 photoinhibition Effects 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- 229920002725 thermoplastic elastomer Polymers 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A61F13/00068—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0203—Adhesive bandages or dressings with fluid retention members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/05—Bandages or dressings; Absorbent pads specially adapted for use with sub-pressure or over-pressure therapy, wound drainage or wound irrigation, e.g. for use with negative-pressure wound therapy [NPWT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/64—Use of materials characterised by their function or physical properties specially adapted to be resorbable inside the body
-
- A61M1/0058—
-
- A61M1/0084—
-
- A61M1/0088—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/71—Suction drainage systems
- A61M1/77—Suction-irrigation systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/92—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing with liquid supply means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/02—Radiation therapy using microwaves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0241—Anaesthetics; Analgesics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0468—Liquids non-physiological
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0238—General characteristics of the apparatus characterised by a particular materials the material being a coating or protective layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0272—Electro-active or magneto-active materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/82—Internal energy supply devices
Definitions
- the present invention relates generally to healing of wounds and wound-treatment therapies. More particularly, but not by way of limitation, the present invention relates to fluid-instillation and negative-pressure wound therapies.
- the wound insert can be incorporated into a wound dressing having other components that facilitate treatment, such as, for example, a drape (e.g., adhesive surgical drape). Instillation fluids may be delivered to the wound insert and held in place at the site of the wound, further improving the efficacy of treatment.
- a drape e.g., adhesive surgical drape
- Wound treatment systems including for example, instillation therapy units such as the V.A.C. Ulta Therapy System, available from Kinetic Concepts, Inc., San Antonio, Tex. U.S.A. may be used to deliver fluids with a more pronounced therapeutic benefit than saline, and indeed, may expand in complexity and capability to be able to deliver a plurality of fluids for different purposes dependent upon wound conditions. It is believed that fluids will be able to be used to reduce infection, to aid with debridement, to improve the dressings removability and to address biofilm buildup in the wound.
- instillation therapy units such as the V.A.C. Ulta Therapy System, available from Kinetic Concepts, Inc., San Antonio, Tex. U.S.A. may be used to deliver fluids with a more pronounced therapeutic benefit than saline, and indeed, may expand in complexity and capability to be able to deliver a plurality of fluids for different purposes dependent upon wound conditions. It is believed that fluids will be able to be used
- wound treatment fluids may contain an active molecule that reacts with various types of plastic and light (including, e.g., ultraviolet light), thus weakening the molecules effectiveness and making its practical delivery to the wound site more difficult.
- Certain embodiments include a wound treatment system comprising: a wound dressing; a fluid storage device comprising a fluid, where the fluid storage device is in fluid communication with the wound dressing; and an energy source configured to direct energy to the fluid and to activate a therapeutic property of the fluid.
- Particular embodiments further comprise a negative pressure source coupled to the wound dressing.
- the fluid comprises molecules with a coating prior to exposure to the energy source.
- the energy source is configured to degrade the protective coating.
- the energy source is configured to activate a component of the fluid that degrades the protective coating.
- the protective coating comprises a polymer shell.
- the protective coating comprises a bioabsorbable glass.
- the protective coating comprises a ceramic.
- the energy source emits ultrasonic energy. In certain embodiments, the energy source emits magnetic energy. In specific embodiments, the energy source emits radio frequency energy. In particular embodiments, the energy source emits ionizing radiation energy. In certain embodiments, the energy source emits microwave energy. In certain embodiments, the energy source emits light energy. In particular embodiments, the energy source is configured to direct energy to the fluid proximal to the wound dressing.
- the energy source is configured to direct energy to the fluid in the conduit.
- the energy source is configured to direct energy to the coupling member.
- the therapeutic property includes an anti-biotic property.
- the therapeutic property includes an analgesic property.
- the therapeutic property aids with debridement of tissue.
- the therapeutic property improves the ability to remove the wound dressing from a wound.
- the therapeutic property reduces biofilm buildup in a wound.
- Particular embodiments include a method of treating a wound, where the method comprises: applying a wound dressing to a wound; transporting fluid to the wound dressing; and directing energy to the fluid and activating a therapeutic property of the fluid.
- the energy is directed to the fluid proximal to the wound dressing.
- Specific embodiments also include applying a negative pressure to the wound dressing.
- Particular embodiments also include providing a fluid storage device and a conduit in fluid communication with the wound dressing.
- the energy is directed to the fluid when the fluid is in the conduit.
- Particular embodiments also include a coupling member coupling the conduit to the wound dressing.
- the energy is directed to the fluid at the coupling member.
- the fluid comprises molecules having a coating and an active agent, and directing energy to the fluid breaks down the protective coating.
- Particular embodiments include a wound treatment system comprising: a wound dressing; a negative pressure source coupled to the wound dressing; a fluid storage device comprising a fluid with molecules having a coating, wherein the fluid storage device is configured for fluid communication with the wound dressing; and an energy source configured to direct energy to the fluid and degrade the coating.
- the energy source directs light energy to the fluid. In certain embodiments, the energy source directs ultrasonic energy to the fluid. In certain embodiments, the energy source directs magnetic energy to the fluid. In particular embodiments, the energy source directs radio frequency energy to the fluid. In certain embodiments, the energy source directs ionizing radiation energy to the fluid. In particular embodiments, a therapeutic property of the fluid is activated when the coating is degraded.
- Certain embodiments include a method of treating a wound, where the method comprises: applying a wound dressing to a wound; transporting fluid to the wound dressing, where the fluid comprises molecules having a coating; and directing energy to the fluid and degrading the coating.
- degrading the coating activates a therapeutic property of the fluid.
- the therapeutic property includes an anti-biotic property.
- the therapeutic property includes an analgesic property.
- the therapeutic property aids with debridement of tissue.
- the therapeutic property improves the ability to remove the wound dressing from a wound.
- the therapeutic property reduces biofilm buildup in a wound.
- FIG. 1 illustrates a schematic diagram of an embodiment of a wound treatment system.
- FIG. 2 illustrates a schematic view of the embodiment of FIG. 1 .
- Coupled is defined as connected, although not necessarily directly, and not necessarily mechanically; two items that are “coupled” may be integral with each other.
- the terms “a” and “an” are defined as one or more unless this disclosure explicitly requires otherwise.
- the terms “substantially,” “approximately,” and “about” are defined as largely but not necessarily wholly what is specified, as understood by a person of ordinary skill in the art.
- a wound dressing that “comprises,” “has,” “includes” or “contains” one or more elements possesses those one or more elements, but is not limited to possessing only those elements.
- the wound dressing in a wound dressing that comprises one of the present wound inserts and a drape, the wound dressing includes the specified elements but is not limited to having only those elements.
- such a wound dressing could also include a connection pad configured to be coupled to a negative pressure wound therapy (NPWT) apparatus (e.g., including a vacuum source and/or a fluid source).
- NGWT negative pressure wound therapy
- a device or structure that is configured in a certain way is configured in at least that way, but it can also be configured in other ways than those specifically described.
- FIG. 1 depicts a schematic diagram of a wound treatment system 100 comprising a wound dressing 110 , a fluid storage device 120 , an energy source 130 , and a negative pressure source 140 .
- a wound treatment system 100 comprising a wound dressing 110 , a fluid storage device 120 , an energy source 130 , and a negative pressure source 140 .
- An overview of the operation of wound treatment system 100 will be provided initially, followed by a more detailed discussion of an exemplary embodiment.
- fluid storage device 120 is in fluid communication with wound dressing 110 via a conduit 150 .
- energy source 130 is coupled to a coupling member 160 , which is in turn coupled to wound dressing 110 .
- fluid storage device 120 comprises a fluid 170 with molecules 175 having a protective coating 176 around an active agent 177 .
- fluid 170 is transported from fluid storage device 120 , through conduit 150 and coupling member 160 to wound dressing 110 .
- energy source 130 can be activated to direct energy towards fluid 170 at coupling member 160 .
- the exposure of fluid 170 to energy emitted from energy source 130 can degrade or break down protective coating 176 and allow active agent 177 to be exposed, thereby activating a therapeutic property of fluid 170 .
- Negative pressure source 140 can then draw fluid 170 from wound dressing 110 into a suitable storage container (not shown).
- fluid storage device 120 and energy source 130 are housed in wound treatment apparatus 180 , along with a supply pump 126 and a control system 127 .
- fluid storage device comprises fluid 170 having molecules 175 with protective coating 176 around active agent 177 .
- control system 127 is used to control supply pump 126 , which pumps fluid 170 to wound dressing 110 .
- negative pressure source 140 may be used to draw fluid from fluid storage device 120 without the use of supply pump 126 .
- wound dressing 110 comprises a wound insert 112 , which is shown placed in wound 116 of a patient (not shown).
- a drape 114 is placed over wound 116 and wound insert 112 such that wound insert 112 is between drape 114 and wound 116 .
- drape 114 is coupled to the skin 118 of the patient.
- wound insert 112 is coupled to a fluid storage device 120 by conduit 150 .
- Wound treatment apparatus 180 may also comprise negative pressure source 140 configured to apply negative pressure to wound insert 112 through a conduit 145 or conduit 150 (if the conduit is a multi-lumen conduit as further explained below).
- Wound insert 112 may be a foam member, which may be open-celled and/or reticulated.
- the wound insert comprises an open-celled reticulated foam.
- An open-celled reticulated foam has a netlike microstructure, with few if any closed cells.
- the porosity can range from 95%-98%, though less porous or more porous foams may be used.
- wound insert 112 may comprise a polyurethane, such as polyurethane-polyester or polyurethane-polyether; polyolefins, such as polypropylenes (PP) or polyethylenes (PE); silicone polymers; polyvinylchloride; polyamides; polyesters; acrylics; thermoplastic elastomers such as styrene-butene-styrene (SBS) or styrene-ethylene-butene-styrene (SEBS); polyether-amide block copolymers (PEBAX); elastomers such as styrene butadiene rubber (SBR); ethylene propylene rubber (EPR); ethylene propylene diene modified rubber (EPDM); natural rubber (NR); ethylene vinyl acetate (EVA); polyvinyl alcohol (PVOH); polyvinyl acetal; or polyvinyl butyral (PVB).
- polyurethane such as polyurethane-polyester or poly
- wound insert 20 may comprise a bioabsorbable polymer, examples of which include polylactic acid, polylactide (PLA), polyglycolic acid, polyglycolide (PGA), and polycaprolactone (PCL).
- PLA polylactide
- PGA polyglycolide
- PCL polycaprolactone
- Wound insert 112 may be of any suitable shape having a depth dimension, including a sheet, a rectangular prism, a cone, a cylinder, a sphere, or any other suitable shape.
- wound treatment apparatus 180 comprises a fluid storage device 120 configured to deliver fluid 170 through conduit 150 to wound dressing 110 .
- fluid 170 may comprise medicinal fluids, antibacterial fluids, or irrigation fluids.
- conduit 150 may comprise a single lumen conduit (e.g., switched between a vacuum source and/or a fluid source) or can comprise multiple single-lumen conduits or a multi-lumen conduit such that, for example, fluid can be delivered and/or negative pressure can be applied to wound dressing 110 individually or simultaneously.
- conduit 150 can comprise multiple lumens, for example, as in a single conduit with a central lumen for application of negative pressure and/or fluid delivery and one or more peripheral lumens disposed adjacent or around the central lumen such that the peripheral lumens can be coupled to a pressure sensor to sense and/or detect a pressure or negative pressure between drape 114 and a wound surface.
- system 100 further comprises a coupling member 160 configured to be coupled to conduit 150 .
- a suitable coupling member 160 is the “V.A.C. T.R.A.C.® Pad,” commercially available from KCI USA, Inc. of San Antonio, Tex., U.S.A.
- a suitable drape 114 includes the “V.A.C.® Drape” commercially available from Kinetic Concepts, Inc., San Antonio, Tex., U.S.A (www.kcil.com).
- Various wound therapy systems and components are commercially available through Kinetic Concepts, Inc. and its affiliates.
- wound treatment apparatus 180 may be configured to deliver instillation fluid to wound 116 , to remove fluid from wound 116 , and to apply negative pressure to wound 116 through drape 114 and wound insert 112 .
- Wound treatment apparatus 180 may be activated to deliver fluid 170 from fluid storage device 120 to wound 116 through conduit 150 coupled to wound insert 112 through coupling member 160 .
- Negative pressure source 140 may also be actuated to provide negative pressure to wound 116 through drape 114 and wound insert 112 .
- Example of fluids 170 that may be delivered to wound 116 include hypochlorous acid (HOCl) and hypochlorite ion (ClO ⁇ , which is also commonly referred to, generally understood to be synonymous with, and may be referred to interchangeably in this disclosure as, OCl ⁇ ), which are examples of effective antimicrobial agents for biocidal action.
- HOCl is typically capable of killing a broad spectrum of microbes (e.g., fungus, bacteria, viruses, fungus, yeast, and the like); often in a relatively short period of time (e.g., is capable of killing greater than 99% of microbes within a period of less than 10 seconds).
- Such antimicrobial agents can be generated or formed by a combination of the present reactive agents and fluid (e.g., water and/or aqueous solution, such as, for example, saline solution) and may be more effective and/or more versatile than antibiotics and other commonly used antimicrobial agents used in wound treatment in the past.
- antibiotics may be bacteria-specific such that testing may be required to determine a suitable antibiotic to use for a specific wound or infection; and/or such that antibiotics may have only limited effectiveness for individual wounds and/or infections (e.g., where testing is not performed and/or where a wound is infected with a plurality of different bacteria).
- antibiotics are typically administered intravenously (systemically) such that antibiotics may kill beneficial bacteria (e.g., in a patient's digestive system) and/or may cause organ damage (e.g., to a patient's liver).
- wound treatment apparatus 180 may be configured to remove spent instillation fluids, secretions, and/or infected tissue from wound 116 .
- Undesirable effluent may be removed by actuating the negative pressure source 140 ; effluent may flow into wound insert, through conduit 145 , and into a waste chamber coupled to wound treatment apparatus 180 .
- fluid 170 comprises molecules 175 having a protective coating 176 surrounding an active agent 177 .
- protective coating 176 may be constructed using a layer-by-layer technique (LbL) where polyallylamine hydrochloride (PAH)/polysodium 4-styrenesulfonate (PSS) may be the layers used to form coating.
- LbL layer-by-layer technique
- PAH polyallylamine hydrochloride
- PSS polysodium 4-styrenesulfonate
- energy source 130 directs energy to fluid 170 and degrades or breaks down protective coating 176 . It is understood that in other embodiments, energy source 130 may direct energy to fluid 150 at other locations within wound treatment system 100 . For example energy source 130 may direct energy to fluid 170 at a location within wound treatment apparatus 180 , along conduit 150 , or directly in wound dressing 110 .
- energy source 130 direct energy to fluid 170 in a location proximal to wound dressing 110 .
- Such a configuration can allow protective coating 176 to remain in place as fluid 170 is transported to wound dressing 110 . This can minimize the effects of exposure of fluid 170 to materials or environmental conditions (e.g., light, temperature, etc.) that may affect active agent 177 of fluid 170 .
- energy source 130 may direct ultrasonic, magnetic, radio, ionizing radiation, microwave or light energy to fluid 170 .
- energy source 130 may direct ultraviolet, infrared or visible light waves to fluid 170 .
- energy source 130 may emit light with a wavelength in the range of approximately 400 nm-450 nm.
- energy source 130 may emit ionizing radiation in the form of gamma rays, x-rays, or electron-beams.
- energy source 130 may activate a component of fluid 170 that in turn degrades or breaks down protective coating 176 .
- fluid 170 may comprise a component that does not degrade protective coating under particular temperature or light conditions. However, when energy source 130 directs energy to fluid 170 , the environmental conditions are changed sufficiently that the component degrades protective coating 176 .
- energy source 130 may be configured to directly degrade protective coating 176 without the use of an additional component in fluid 170 .
- active agent 177 can provide a therapeutic benefit to the patient.
- therapeutic benefits include antibiotic and analgesic properties. Therapeutic properties may also aid with debridement, improve the ability to remove the wound dressing, and reduce biofilm buildup in the wound.
- Wound treatment system 100 can reduce the amount of degradation of active agent 177 during transport of fluid 170 throughout.
- the protective coating may comprise an ultraviolet-activated protective cover which is partially activated to break down by ambient light while traveling through the conduit to the wound dressing (or during storage in the fluid storage device). The breakdown of the protective coating can then be completed by an energy source proximal to the wound dressing.
- the fluid may comprise molecules constructed so that the active agent is inhibited by a light sensitive branch.
- a light sensitive branch For example, exposure to ultraviolet light could be used to break the branch and activate the compound.
- Such configurations could be of use with active agents that have a short active life due to a spontaneous reaction or from interaction with the surrounding environment.
- photoinhibition could also be used to control the behavior of the active agents.
- Certain exemplary embodiments may also comprise a clotting agent, e.g. fibrin, chitosan, and trivalent salts, such as Fe +++ & Al +++ .
- a Fe+++ compound such as ferric chloride
- a glucose sensitive microcapsule e.g., glutaraldehyde cross-linked hemoglobin and glucose oxidase
- glucose which may be present in wound fluid or instilled by the user
- the permeability of the microcapsule increases allowing for the release of the Fe+++ agent.
- the wound fluid may also enter the microcapsule and initiate the clotting reaction.
- the clotting agent may be applied to the wound dressing.
- the clotting agent may be protected by an active layer capable of being activated by haemoglobin and releasing the clotting agent locally.
- the clotting agent is the active agent in a molecule with a protective coating, and may be activated as described in previous exemplary embodiments.
- thrombin may be utilized in the clotting mechanism, for example, in combination with fibrinogen.
- thrombin may be inhibited or ‘blocked’ by p-Amidinophenyl-(E)-4-diethylamino-2-hydroxy-alpha-methylcinnamate hydrochloride through covalent bonding.
- light e.g., at approximately 366 nm
- the fluid may comprise multiple molecules, particles or agents in the fluid which are activated by different wavelengths of light or frequencies of energy, which could be delivered at the point of entry to the wound or once in the wound to activate them.
- a light-activated group e.g. the thrombin-fibrinogen group described above
- a group could be grafted that would liberate cations when exposed to light at a wavelength other than 366 nm.
- Non-limiting examples of such chemical groups that could be used to liberate cations include (photoacid generators [PAGs]) in the 150 nm-350 nm UV light range are carboranes, and diphenyliodonium nitrate (activated at about 226 nm).
- a simple alternative, avoiding grafting, would be to mix the two sensitive materials (clotting agent and cationic agent).
- the cationic agent would be acidic and could aid in debriding
- local activation of the energy source may be utilized in the wound by either a coating on the wound insert local to a targeted issue such as necrotic tissue or by localised external stimulation.
- multiple molecules in the wound fluid may be utilized which activate based upon reaction with biomarkers in the wound (e.g., inflammatory response markers).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Materials Engineering (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- External Artificial Organs (AREA)
Abstract
Systems and methods of stimulating or activating fluids for use in wound treatment systems.
Description
- This application is a continuation of U.S. patent application Ser. No. 15/456,886, filed Mar. 13, 2017, which is a continuation of U.S. patent application Ser. No. 14/216,522, filed Mar. 17, 2014, now U.S. Pat. No. 9,623,224, which claims priority to U.S. patent application Ser. No. 13/477,741, filed May 22, 2012, now U.S. Pat. No. 8,708,981, which claims priority to U.S. Provisional Patent Application Ser. No. 61/490,150, filed May 26, 2011, the entire contents of which are incorporated herein by reference.
- The present invention relates generally to healing of wounds and wound-treatment therapies. More particularly, but not by way of limitation, the present invention relates to fluid-instillation and negative-pressure wound therapies.
- Clinical studies and practice have shown that providing therapeutic fluids, particularly in conjunction with reduced pressure, in proximity to a tissue site augments and accelerates the growth of new tissue at the tissue site. The applications of this phenomenon are numerous, but application of reduced pressure has been particularly successful in treating wounds. This treatment (frequently referred to in the medical community as “negative pressure wound therapy,” “reduced pressure therapy,” or “vacuum therapy”) provides a number of benefits, including faster healing and increased formulation of granulation tissue. Typically, reduced pressure is applied to tissue through a wound insert (e.g., a porous pad or other manifold device). The wound insert typically contains cells or pores that are capable of distributing reduced pressure to the tissue and channeling fluids that are drawn from the tissue. The wound insert can be incorporated into a wound dressing having other components that facilitate treatment, such as, for example, a drape (e.g., adhesive surgical drape). Instillation fluids may be delivered to the wound insert and held in place at the site of the wound, further improving the efficacy of treatment.
- Wound treatment systems, including for example, instillation therapy units such as the V.A.C. Ulta Therapy System, available from Kinetic Concepts, Inc., San Antonio, Tex. U.S.A. may be used to deliver fluids with a more pronounced therapeutic benefit than saline, and indeed, may expand in complexity and capability to be able to deliver a plurality of fluids for different purposes dependent upon wound conditions. It is believed that fluids will be able to be used to reduce infection, to aid with debridement, to improve the dressings removability and to address biofilm buildup in the wound.
- Certain systems offer fluids with molecules which are tailored and effective to provide the benefits described the above, but often are not designed for use with a system which doses the fluid over time and exposes the fluid to tubing and other plastic components. For example, wound treatment fluids may contain an active molecule that reacts with various types of plastic and light (including, e.g., ultraviolet light), thus weakening the molecules effectiveness and making its practical delivery to the wound site more difficult.
- It is therefore desirable in systems with molecules which may be susceptible to negative impacts of contact with certain materials or light to protect them or render them immune to these range of deleterious effects until the system determines they should be active.
- As described herein, it is possible to provide for control of the stimulation or activation of fluids used in wound treatment systems.
- Systems and methods of stimulating or activating fluids for use in wound treatment systems are presented.
- Certain embodiments include a wound treatment system comprising: a wound dressing; a fluid storage device comprising a fluid, where the fluid storage device is in fluid communication with the wound dressing; and an energy source configured to direct energy to the fluid and to activate a therapeutic property of the fluid. Particular embodiments further comprise a negative pressure source coupled to the wound dressing. In certain embodiments, the fluid comprises molecules with a coating prior to exposure to the energy source. In particular embodiments, the energy source is configured to degrade the protective coating. In specific embodiments, the energy source is configured to activate a component of the fluid that degrades the protective coating.
- In certain embodiments, the protective coating comprises a polymer shell. In particular embodiments, the protective coating comprises a bioabsorbable glass. In specific embodiments, the protective coating comprises a ceramic.
- In particular embodiments, the energy source emits ultrasonic energy. In certain embodiments, the energy source emits magnetic energy. In specific embodiments, the energy source emits radio frequency energy. In particular embodiments, the energy source emits ionizing radiation energy. In certain embodiments, the energy source emits microwave energy. In certain embodiments, the energy source emits light energy. In particular embodiments, the energy source is configured to direct energy to the fluid proximal to the wound dressing.
- Specific embodiments comprise a conduit in fluid communication with the fluid storage device and the wound dressing. In certain embodiments, the energy source is configured to direct energy to the fluid in the conduit. Particular embodiments comprise a coupling member coupling the conduit to the wound dressing. In certain embodiments, the energy source is configured to direct energy to the coupling member. In specific embodiments, the therapeutic property includes an anti-biotic property. In certain embodiments, the therapeutic property includes an analgesic property. In particular embodiments, the therapeutic property aids with debridement of tissue. In certain embodiments, the therapeutic property improves the ability to remove the wound dressing from a wound. In specific embodiments, the therapeutic property reduces biofilm buildup in a wound.
- Particular embodiments include a method of treating a wound, where the method comprises: applying a wound dressing to a wound; transporting fluid to the wound dressing; and directing energy to the fluid and activating a therapeutic property of the fluid. In certain embodiments, the energy is directed to the fluid proximal to the wound dressing. Specific embodiments also include applying a negative pressure to the wound dressing. Particular embodiments also include providing a fluid storage device and a conduit in fluid communication with the wound dressing. In certain embodiments, the energy is directed to the fluid when the fluid is in the conduit. Particular embodiments also include a coupling member coupling the conduit to the wound dressing. In specific embodiments, the energy is directed to the fluid at the coupling member. In certain embodiments, the fluid comprises molecules having a coating and an active agent, and directing energy to the fluid breaks down the protective coating.
- Particular embodiments include a wound treatment system comprising: a wound dressing; a negative pressure source coupled to the wound dressing; a fluid storage device comprising a fluid with molecules having a coating, wherein the fluid storage device is configured for fluid communication with the wound dressing; and an energy source configured to direct energy to the fluid and degrade the coating.
- In specific embodiments, the energy source directs light energy to the fluid. In certain embodiments, the energy source directs ultrasonic energy to the fluid. In certain embodiments, the energy source directs magnetic energy to the fluid. In particular embodiments, the energy source directs radio frequency energy to the fluid. In certain embodiments, the energy source directs ionizing radiation energy to the fluid. In particular embodiments, a therapeutic property of the fluid is activated when the coating is degraded.
- Certain embodiments include a method of treating a wound, where the method comprises: applying a wound dressing to a wound; transporting fluid to the wound dressing, where the fluid comprises molecules having a coating; and directing energy to the fluid and degrading the coating. In specific embodiments, degrading the coating activates a therapeutic property of the fluid. In particular embodiments, the therapeutic property includes an anti-biotic property. In certain embodiments, the therapeutic property includes an analgesic property. In particular embodiments, the therapeutic property aids with debridement of tissue. In certain embodiments, the therapeutic property improves the ability to remove the wound dressing from a wound. In particular embodiments, the therapeutic property reduces biofilm buildup in a wound.
- The following drawings illustrate by way of example and not limitation. For the sake of brevity and clarity, every feature of a given structure is not always labeled in every figure in which that structure appears. Identical reference numbers do not necessarily indicate an identical structure. Rather, the same reference number may be used to indicate a similar feature or a feature with similar functionality, as may non-identical reference numbers.
-
FIG. 1 illustrates a schematic diagram of an embodiment of a wound treatment system. -
FIG. 2 illustrates a schematic view of the embodiment ofFIG. 1 . - The term “coupled” is defined as connected, although not necessarily directly, and not necessarily mechanically; two items that are “coupled” may be integral with each other. The terms “a” and “an” are defined as one or more unless this disclosure explicitly requires otherwise. The terms “substantially,” “approximately,” and “about” are defined as largely but not necessarily wholly what is specified, as understood by a person of ordinary skill in the art.
- The terms “comprise” (and any form of comprise, such as “comprises” and “comprising”), “have” (and any form of have, such as “has” and “having”), “include” (and any form of include, such as “includes” and “including”) and “contain” (and any form of contain, such as “contains” and “containing”) are open-ended linking verbs. As a result, a wound-treatment method that “comprises,” “has,” “includes” or “contains” one or more steps possesses those one or more steps, but is not limited to possessing only those one or more steps. Likewise, a wound dressing that “comprises,” “has,” “includes” or “contains” one or more elements possesses those one or more elements, but is not limited to possessing only those elements. For example, in a wound dressing that comprises one of the present wound inserts and a drape, the wound dressing includes the specified elements but is not limited to having only those elements. For example, such a wound dressing could also include a connection pad configured to be coupled to a negative pressure wound therapy (NPWT) apparatus (e.g., including a vacuum source and/or a fluid source).
- Further, a device or structure that is configured in a certain way is configured in at least that way, but it can also be configured in other ways than those specifically described.
- Turning now to the figures,
FIG. 1 depicts a schematic diagram of awound treatment system 100 comprising a wound dressing 110, afluid storage device 120, anenergy source 130, and anegative pressure source 140. An overview of the operation ofwound treatment system 100 will be provided initially, followed by a more detailed discussion of an exemplary embodiment. - In the exemplary embodiment shown in
FIG. 1 ,fluid storage device 120 is in fluid communication with wound dressing 110 via aconduit 150. In addition,energy source 130 is coupled to acoupling member 160, which is in turn coupled to wound dressing 110. - In this exemplary embodiment,
fluid storage device 120 comprises a fluid 170 withmolecules 175 having aprotective coating 176 around anactive agent 177. During operation,fluid 170 is transported fromfluid storage device 120, throughconduit 150 andcoupling member 160 to wound dressing 110. In the embodiment shown,energy source 130 can be activated to direct energy towardsfluid 170 atcoupling member 160. The exposure offluid 170 to energy emitted fromenergy source 130 can degrade or break downprotective coating 176 and allowactive agent 177 to be exposed, thereby activating a therapeutic property offluid 170.Negative pressure source 140 can then draw fluid 170 from wound dressing 110 into a suitable storage container (not shown). - Referring now to
FIG. 2 , a more detailed view and discussion ofwound treatment system 100 is provided. In this embodiment,fluid storage device 120 andenergy source 130 are housed inwound treatment apparatus 180, along with asupply pump 126 and acontrol system 127. As previously explained, fluid storage device comprises fluid 170 havingmolecules 175 withprotective coating 176 aroundactive agent 177. In this embodiment,control system 127 is used to controlsupply pump 126, which pumpsfluid 170 to wound dressing 110. It is understood that in other exemplary embodiments,negative pressure source 140 may be used to draw fluid fromfluid storage device 120 without the use ofsupply pump 126. - In this embodiment wound dressing 110 comprises a
wound insert 112, which is shown placed inwound 116 of a patient (not shown). Adrape 114 is placed overwound 116 and woundinsert 112 such that woundinsert 112 is betweendrape 114 and wound 116. In the illustrated embodiment,drape 114 is coupled to theskin 118 of the patient. In this exemplary embodiment, woundinsert 112 is coupled to afluid storage device 120 byconduit 150.Wound treatment apparatus 180 may also comprisenegative pressure source 140 configured to apply negative pressure to woundinsert 112 through aconduit 145 or conduit 150 (if the conduit is a multi-lumen conduit as further explained below). -
Wound insert 112 may be a foam member, which may be open-celled and/or reticulated. In specific embodiments, the wound insert comprises an open-celled reticulated foam. An open-celled reticulated foam has a netlike microstructure, with few if any closed cells. In certain embodiments, the porosity can range from 95%-98%, though less porous or more porous foams may be used. - In certain embodiments, wound
insert 112 may comprise a polyurethane, such as polyurethane-polyester or polyurethane-polyether; polyolefins, such as polypropylenes (PP) or polyethylenes (PE); silicone polymers; polyvinylchloride; polyamides; polyesters; acrylics; thermoplastic elastomers such as styrene-butene-styrene (SBS) or styrene-ethylene-butene-styrene (SEBS); polyether-amide block copolymers (PEBAX); elastomers such as styrene butadiene rubber (SBR); ethylene propylene rubber (EPR); ethylene propylene diene modified rubber (EPDM); natural rubber (NR); ethylene vinyl acetate (EVA); polyvinyl alcohol (PVOH); polyvinyl acetal; or polyvinyl butyral (PVB). Additionally, wound insert 20 may comprise a bioabsorbable polymer, examples of which include polylactic acid, polylactide (PLA), polyglycolic acid, polyglycolide (PGA), and polycaprolactone (PCL). Methods of manufacturing open-celled reticulated foam are well known. Open-celled reticulated foam is commercially available from a variety of sources, including Kinetic Concepts, Inc., San Antonio, Tex., U.S.A. (www.kcil.com). -
Wound insert 112 may be of any suitable shape having a depth dimension, including a sheet, a rectangular prism, a cone, a cylinder, a sphere, or any other suitable shape. - In the exemplary embodiment shown, wound
treatment apparatus 180 comprises afluid storage device 120 configured to deliver fluid 170 throughconduit 150 to wound dressing 110. In certain exemplary embodiments,fluid 170 may comprise medicinal fluids, antibacterial fluids, or irrigation fluids. - In specific exemplary embodiments,
conduit 150 may comprise a single lumen conduit (e.g., switched between a vacuum source and/or a fluid source) or can comprise multiple single-lumen conduits or a multi-lumen conduit such that, for example, fluid can be delivered and/or negative pressure can be applied to wound dressing 110 individually or simultaneously. In otherexemplary embodiments conduit 150 can comprise multiple lumens, for example, as in a single conduit with a central lumen for application of negative pressure and/or fluid delivery and one or more peripheral lumens disposed adjacent or around the central lumen such that the peripheral lumens can be coupled to a pressure sensor to sense and/or detect a pressure or negative pressure betweendrape 114 and a wound surface. In the embodiment shown,system 100 further comprises acoupling member 160 configured to be coupled toconduit 150. One example of asuitable coupling member 160 is the “V.A.C. T.R.A.C.® Pad,” commercially available from KCI USA, Inc. of San Antonio, Tex., U.S.A. One example of asuitable drape 114 includes the “V.A.C.® Drape” commercially available from Kinetic Concepts, Inc., San Antonio, Tex., U.S.A (www.kcil.com). Various wound therapy systems and components are commercially available through Kinetic Concepts, Inc. and its affiliates. - In the embodiment shown in
FIG. 2 , woundtreatment apparatus 180 may be configured to deliver instillation fluid to wound 116, to remove fluid fromwound 116, and to apply negative pressure to wound 116 throughdrape 114 and woundinsert 112. -
Wound treatment apparatus 180 may be activated to deliver fluid 170 fromfluid storage device 120 to wound 116 throughconduit 150 coupled to woundinsert 112 throughcoupling member 160.Negative pressure source 140 may also be actuated to provide negative pressure to wound 116 throughdrape 114 and woundinsert 112. - Example of
fluids 170 that may be delivered to wound 116 include hypochlorous acid (HOCl) and hypochlorite ion (ClO−, which is also commonly referred to, generally understood to be synonymous with, and may be referred to interchangeably in this disclosure as, OCl−), which are examples of effective antimicrobial agents for biocidal action. For example, HOCl is typically capable of killing a broad spectrum of microbes (e.g., fungus, bacteria, viruses, fungus, yeast, and the like); often in a relatively short period of time (e.g., is capable of killing greater than 99% of microbes within a period of less than 10 seconds). - Such antimicrobial agents can be generated or formed by a combination of the present reactive agents and fluid (e.g., water and/or aqueous solution, such as, for example, saline solution) and may be more effective and/or more versatile than antibiotics and other commonly used antimicrobial agents used in wound treatment in the past. For example, antibiotics may be bacteria-specific such that testing may be required to determine a suitable antibiotic to use for a specific wound or infection; and/or such that antibiotics may have only limited effectiveness for individual wounds and/or infections (e.g., where testing is not performed and/or where a wound is infected with a plurality of different bacteria).
- Such testing may take as long as several days to determine an appropriate antibiotic, delaying treatment or selection of an effective antibiotic. Additionally, bacteria may develop resistance to antibiotics, such that antibiotics may have reduced effectiveness after an amount of time. Further, antibiotics are typically administered intravenously (systemically) such that antibiotics may kill beneficial bacteria (e.g., in a patient's digestive system) and/or may cause organ damage (e.g., to a patient's liver).
- Further, wound
treatment apparatus 180 may be configured to remove spent instillation fluids, secretions, and/or infected tissue fromwound 116. Undesirable effluent may be removed by actuating thenegative pressure source 140; effluent may flow into wound insert, throughconduit 145, and into a waste chamber coupled to woundtreatment apparatus 180. - As previously described, in this exemplary embodiment,
fluid 170 comprisesmolecules 175 having aprotective coating 176 surrounding anactive agent 177. In certain embodiments,protective coating 176 may be constructed using a layer-by-layer technique (LbL) where polyallylamine hydrochloride (PAH)/polysodium 4-styrenesulfonate (PSS) may be the layers used to form coating. - During operation, as
fluid 170 is initially transported fromfluid storage device 120 and throughconduit 150,protective coating 176 surroundsactive agent 177 ofmolecules 175. Upon reachingcoupling member 160,energy source 130 directs energy tofluid 170 and degrades or breaks downprotective coating 176. It is understood that in other embodiments,energy source 130 may direct energy tofluid 150 at other locations withinwound treatment system 100. Forexample energy source 130 may direct energy tofluid 170 at a location withinwound treatment apparatus 180, alongconduit 150, or directly in wound dressing 110. - In certain embodiments, it may be beneficial to have
energy source 130 direct energy tofluid 170 in a location proximal to wound dressing 110. Such a configuration can allowprotective coating 176 to remain in place asfluid 170 is transported to wound dressing 110. This can minimize the effects of exposure offluid 170 to materials or environmental conditions (e.g., light, temperature, etc.) that may affectactive agent 177 offluid 170. - In certain embodiments,
energy source 130 may direct ultrasonic, magnetic, radio, ionizing radiation, microwave or light energy tofluid 170. In specific embodiments,energy source 130 may direct ultraviolet, infrared or visible light waves tofluid 170. In certain embodiments,energy source 130 may emit light with a wavelength in the range of approximately 400 nm-450 nm. In particular embodiments,energy source 130 may emit ionizing radiation in the form of gamma rays, x-rays, or electron-beams. - In particular embodiments,
energy source 130 may activate a component offluid 170 that in turn degrades or breaks downprotective coating 176. For example, fluid 170 may comprise a component that does not degrade protective coating under particular temperature or light conditions. However, whenenergy source 130 directs energy tofluid 170, the environmental conditions are changed sufficiently that the component degradesprotective coating 176. In other embodiments,energy source 130 may be configured to directly degradeprotective coating 176 without the use of an additional component influid 170. - After
protective coating 176 is degraded,active agent 177 can provide a therapeutic benefit to the patient. Non-limiting examples of the therapeutic benefits that may be provided to a patient include antibiotic and analgesic properties. Therapeutic properties may also aid with debridement, improve the ability to remove the wound dressing, and reduce biofilm buildup in the wound. - By protecting
active agent 177 inprotective coating 176 untilfluid 170 is proximal to wound dressing 110, it is believed that more accurate dosing ofactive agent 177 can be achieved. For example, in certain prior art wound treatment systems that do not provide for protection of an active ingredient, it may be necessary to increase the dosage or concentrations levels of the active ingredient in a fluid container to account for degradation during delivery.Wound treatment system 100 can reduce the amount of degradation ofactive agent 177 during transport offluid 170 throughout. - The various illustrative embodiments of devices, systems, and methods described herein are not intended to be limited to the particular forms disclosed. Rather, they include all modifications and alternatives falling within the scope of the claims. For example, in certain exemplary embodiments, the protective coating may comprise an ultraviolet-activated protective cover which is partially activated to break down by ambient light while traveling through the conduit to the wound dressing (or during storage in the fluid storage device). The breakdown of the protective coating can then be completed by an energy source proximal to the wound dressing.
- In certain exemplary embodiments, rather than a protective coating, the fluid may comprise molecules constructed so that the active agent is inhibited by a light sensitive branch. In such embodiments, for example, exposure to ultraviolet light could be used to break the branch and activate the compound. Such configurations could be of use with active agents that have a short active life due to a spontaneous reaction or from interaction with the surrounding environment. In particular embodiments, photoinhibition could also be used to control the behavior of the active agents.
- Certain exemplary embodiments may also comprise a clotting agent, e.g. fibrin, chitosan, and trivalent salts, such as Fe+++ & Al+++. In particular embodiments, a Fe+++ compound (such as ferric chloride) can be encapsulated in a glucose sensitive microcapsule (e.g., glutaraldehyde cross-linked hemoglobin and glucose oxidase). On encountering glucose (which may be present in wound fluid or instilled by the user), the permeability of the microcapsule increases allowing for the release of the Fe+++ agent. The wound fluid may also enter the microcapsule and initiate the clotting reaction. In specific embodiments, the clotting agent may be applied to the wound dressing. The clotting agent may be protected by an active layer capable of being activated by haemoglobin and releasing the clotting agent locally. In certain embodiments, the clotting agent is the active agent in a molecule with a protective coating, and may be activated as described in previous exemplary embodiments.
- In particular embodiments, thrombin may be utilized in the clotting mechanism, for example, in combination with fibrinogen. In specific embodiments, thrombin may be inhibited or ‘blocked’ by p-Amidinophenyl-(E)-4-diethylamino-2-hydroxy-alpha-methylcinnamate hydrochloride through covalent bonding. By exposing the blocked thrombin to light (e.g., at approximately 366 nm) the thrombin may unblocked and clotting can occur.
- In other exemplary embodiments, the fluid may comprise multiple molecules, particles or agents in the fluid which are activated by different wavelengths of light or frequencies of energy, which could be delivered at the point of entry to the wound or once in the wound to activate them. For example, in certain embodiments a light-activated group (e.g. the thrombin-fibrinogen group described above) could be grafted onto a molecule at one location. At another location on the molecule, a group could be grafted that would liberate cations when exposed to light at a wavelength other than 366 nm. Non-limiting examples of such chemical groups that could be used to liberate cations include (photoacid generators [PAGs]) in the 150 nm-350 nm UV light range are carboranes, and diphenyliodonium nitrate (activated at about 226 nm). A simple alternative, avoiding grafting, would be to mix the two sensitive materials (clotting agent and cationic agent). The cationic agent would be acidic and could aid in debriding
- In particular exemplary embodiments, local activation of the energy source may be utilized in the wound by either a coating on the wound insert local to a targeted issue such as necrotic tissue or by localised external stimulation. In certain exemplary embodiments, multiple molecules in the wound fluid may be utilized which activate based upon reaction with biomarkers in the wound (e.g., inflammatory response markers).
- The claims are not intended to include, and should not be interpreted to include, means-plus- or step-plus-function limitations, unless such a limitation is explicitly recited in a given claim using the phrase(s) “means for” or “step for,” respectively.
Claims (20)
1. A system for treating a wound, comprising:
a fluid storage device having a fluid comprising a therapeutic agent;
a negative-pressure source configured to draw the fluid from the fluid storage device through a wound dressing; and
an energy source configured to direct energy to the fluid to activate the therapeutic agent.
2. The system of claim 1 , wherein the therapeutic agent comprises molecules having a protective coating prior to exposure to the energy source.
3. The system of claim 2 , wherein the energy source is configured to degrade the protective coating.
4. The system of claim 2 , wherein the energy source is configured to activate a component of the fluid that degrades the protective coating.
5. The system of claim 1 , wherein the energy source is configured to direct energy to the fluid proximal to the wound dressing.
6. A system for treating a wound, comprising:
a fluid storage device having a fluid comprising a therapeutic agent;
a supply pump configured to move the fluid from the fluid storage device into a wound dressing; and
an energy source configured to direct energy to the fluid to activate the therapeutic agent.
7. The system of claim 6 , wherein the energy source is configured to emit ultrasonic energy.
8. The system of claim 6 , wherein the energy source is configured to emit magnetic energy.
9. The system of claim 6 , wherein the energy source is configured to emit radio frequency energy.
10. The system of claim 6 , wherein the energy source is configured to emit ionizing radiation energy.
11. The system of claim 6 , wherein the energy source is configured to emit microwave energy.
12. A method of treating a wound, the method comprising:
applying negative pressure to a wound dressing;
drawing fluid through the wound dressing; and
directing energy to the fluid proximal to the wound dressing and activating a therapeutic property of the fluid.
13. The method of claim 12 , wherein activating a therapeutic property of the fluid comprises degrading a coating of a molecule in the fluid.
14. The method of claim 12 , wherein the therapeutic property includes an anti-biotic property.
15. The method of claim 12 , wherein the therapeutic property includes an analgesic property.
16. The method of claim 12 , wherein the therapeutic property aids with debridement the wound.
17. A method of treating a wound, the method comprising:
pumping fluid through a wound dressing; and
directing energy to the fluid proximal to the wound dressing and activating a therapeutic property of the fluid.
18. The method of claim 17 , wherein the therapeutic property comprises molecules with a protective coating and activating the therapeutic property comprises degrading the protective coating.
19. The method of claim 17 , wherein activating a therapeutic property of the fluid further comprises reducing biofilm buildup.
20. The method of claim 17 , wherein activating a therapeutic property further comprises debriding the wound.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/517,788 US20190336739A1 (en) | 2011-05-26 | 2019-07-22 | Systems and methods of stimulation and activation of fluids for use with instillation therapy |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161490150P | 2011-05-26 | 2011-05-26 | |
US13/477,741 US8708981B2 (en) | 2011-05-26 | 2012-05-22 | Systems and methods of stimulation and activation of fluids for use with instillation therapy |
US14/216,522 US9623224B2 (en) | 2011-05-26 | 2014-03-17 | Systems and methods of stimulation and activation of fluids for use with instillation therapy |
US15/456,886 US10406337B2 (en) | 2011-05-26 | 2017-03-13 | Systems and methods of stimulation and activation of fluids for use with instillation therapy |
US16/517,788 US20190336739A1 (en) | 2011-05-26 | 2019-07-22 | Systems and methods of stimulation and activation of fluids for use with instillation therapy |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/456,886 Continuation US10406337B2 (en) | 2011-05-26 | 2017-03-13 | Systems and methods of stimulation and activation of fluids for use with instillation therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190336739A1 true US20190336739A1 (en) | 2019-11-07 |
Family
ID=46172966
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/477,741 Active 2032-06-22 US8708981B2 (en) | 2011-05-26 | 2012-05-22 | Systems and methods of stimulation and activation of fluids for use with instillation therapy |
US14/216,522 Active 2033-05-21 US9623224B2 (en) | 2011-05-26 | 2014-03-17 | Systems and methods of stimulation and activation of fluids for use with instillation therapy |
US15/456,886 Active 2033-05-31 US10406337B2 (en) | 2011-05-26 | 2017-03-13 | Systems and methods of stimulation and activation of fluids for use with instillation therapy |
US16/517,788 Abandoned US20190336739A1 (en) | 2011-05-26 | 2019-07-22 | Systems and methods of stimulation and activation of fluids for use with instillation therapy |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/477,741 Active 2032-06-22 US8708981B2 (en) | 2011-05-26 | 2012-05-22 | Systems and methods of stimulation and activation of fluids for use with instillation therapy |
US14/216,522 Active 2033-05-21 US9623224B2 (en) | 2011-05-26 | 2014-03-17 | Systems and methods of stimulation and activation of fluids for use with instillation therapy |
US15/456,886 Active 2033-05-31 US10406337B2 (en) | 2011-05-26 | 2017-03-13 | Systems and methods of stimulation and activation of fluids for use with instillation therapy |
Country Status (7)
Country | Link |
---|---|
US (4) | US8708981B2 (en) |
EP (1) | EP2714117B2 (en) |
JP (1) | JP6449015B2 (en) |
CN (2) | CN106176046A (en) |
AU (2) | AU2012258916B2 (en) |
CA (1) | CA2834702C (en) |
WO (1) | WO2012162287A1 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10968543B2 (en) | 2011-12-01 | 2021-04-06 | Convatec Technologies Inc. | Wound dressing for use in vacuum therapy |
US11116884B2 (en) | 2010-12-08 | 2021-09-14 | Convatec Technologies Inc. | Integrated system for assessing wound exudates |
US11135315B2 (en) | 2010-11-30 | 2021-10-05 | Convatec Technologies Inc. | Composition for detecting biofilms on viable tissues |
US20220031519A1 (en) * | 2018-11-29 | 2022-02-03 | Nexa Medical Limited | Wound-Dressing Conditioning Device |
US11241525B2 (en) | 2010-12-08 | 2022-02-08 | Convatec Technologies Inc. | Wound exudate monitor accessory |
US11241339B2 (en) | 2011-11-29 | 2022-02-08 | Convatec Inc. | Perforated binder for laminated wound dressing |
US11266774B2 (en) | 2016-07-08 | 2022-03-08 | Convatec Technologies Inc. | Fluid collection apparatus |
US11286601B2 (en) | 2012-12-20 | 2022-03-29 | Convatec Technologies, Inc. | Processing of chemically modified cellulosic fibres |
US11331221B2 (en) | 2019-12-27 | 2022-05-17 | Convatec Limited | Negative pressure wound dressing |
US11452808B2 (en) | 2016-07-08 | 2022-09-27 | Convatec Technologies Inc. | Fluid flow sensing |
US11458044B2 (en) | 2008-09-29 | 2022-10-04 | Convatec Technologies Inc. | Wound dressing |
US11583430B2 (en) | 2011-09-02 | 2023-02-21 | Convatec Ltd. | Skin contact material |
US11596554B2 (en) | 2016-07-08 | 2023-03-07 | Convatec Technologies Inc. | Flexible negative pressure system |
US11628093B2 (en) | 2008-05-08 | 2023-04-18 | Convatec Technologies, Inc. | Wound dressing |
US11723808B2 (en) | 2016-03-30 | 2023-08-15 | Convatec Technologies Inc. | Detecting microbial infections in wounds |
US11740241B2 (en) | 2016-03-30 | 2023-08-29 | Synovo Gmbh | Construct including an anchor, an enzyme recognition site and an indicator region for detecting microbial infection in wounds |
US11771819B2 (en) | 2019-12-27 | 2023-10-03 | Convatec Limited | Low profile filter devices suitable for use in negative pressure wound therapy systems |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8708981B2 (en) * | 2011-05-26 | 2014-04-29 | Kci Licensing, Inc. | Systems and methods of stimulation and activation of fluids for use with instillation therapy |
EP2714120B1 (en) | 2011-05-27 | 2017-10-18 | KCI Licensing, Inc. | Systems and methods for delivering fluid to a wound therapy dressing |
CN103702646B (en) | 2011-06-24 | 2016-03-30 | 凯希特许有限公司 | The decompression of tissue fixation elements is adopted to apply part |
EP3169382B1 (en) | 2014-07-18 | 2018-09-26 | KCI Licensing, Inc. | Instillation cartridge for vacuum actuated fluid delivery |
EP3851134A1 (en) * | 2014-07-18 | 2021-07-21 | 3M Innovative Properties Company | Disposable cartridge for vacuum actuated fluid delivery |
CN104174111A (en) * | 2014-09-11 | 2014-12-03 | 昆山韦睿医疗科技有限公司 | Negative pressure wound treatment device and control method thereof |
CN104815385A (en) * | 2015-04-23 | 2015-08-05 | 广州新诚生物科技有限公司 | Multi-functional negative pressure drainage system |
US20170028111A1 (en) | 2015-07-29 | 2017-02-02 | Innovative Therapies, Inc. | Wound therapy device pressure monitoring and control system |
EP3397297A1 (en) * | 2015-12-29 | 2018-11-07 | KCI Licensing, Inc. | System and methods for treatment of wounds with negative pressure and peroxy pyruvic acid |
CN106730301B (en) * | 2017-01-19 | 2019-12-13 | 赵金花 | Wound nursing device |
WO2018140386A2 (en) * | 2017-01-27 | 2018-08-02 | Kci Licensing, Inc. | Multi-layer abdominal closure dressing with instillation capabilities |
US11918549B2 (en) | 2017-08-25 | 2024-03-05 | AZ Solutions LLC | System and method for wound treatment and irrigation |
US10960129B2 (en) | 2017-08-25 | 2021-03-30 | AZ Solutions LLC | System and method for patient skin treatment and irrigation |
WO2021178568A1 (en) | 2020-03-03 | 2021-09-10 | Deroyal Industries, Inc. | Negative pressure wound therapy instillation system |
Family Cites Families (151)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1355846A (en) | 1920-02-06 | 1920-10-19 | David A Rannells | Medical appliance |
US2547758A (en) | 1949-01-05 | 1951-04-03 | Wilmer B Keeling | Instrument for treating the male urethra |
US2632443A (en) | 1949-04-18 | 1953-03-24 | Eleanor P Lesher | Surgical dressing |
GB692578A (en) | 1949-09-13 | 1953-06-10 | Minnesota Mining & Mfg | Improvements in or relating to drape sheets for surgical use |
US2682873A (en) | 1952-07-30 | 1954-07-06 | Johnson & Johnson | General purpose protective dressing |
NL189176B (en) | 1956-07-13 | 1900-01-01 | Hisamitsu Pharmaceutical Co | PLASTER BASED ON A SYNTHETIC RUBBER. |
US2969057A (en) | 1957-11-04 | 1961-01-24 | Brady Co W H | Nematodic swab |
US3066672A (en) | 1960-09-27 | 1962-12-04 | Jr William H Crosby | Method and apparatus for serial sampling of intestinal juice |
US3367332A (en) | 1965-08-27 | 1968-02-06 | Gen Electric | Product and process for establishing a sterile area of skin |
US3520300A (en) | 1967-03-15 | 1970-07-14 | Amp Inc | Surgical sponge and suction device |
US3568675A (en) | 1968-08-30 | 1971-03-09 | Clyde B Harvey | Fistula and penetrating wound dressing |
US3682180A (en) | 1970-06-08 | 1972-08-08 | Coilform Co Inc | Drain clip for surgical drain |
BE789293Q (en) | 1970-12-07 | 1973-01-15 | Parke Davis & Co | MEDICO-SURGICAL DRESSING FOR BURNS AND SIMILAR LESIONS |
US3826254A (en) | 1973-02-26 | 1974-07-30 | Verco Ind | Needle or catheter retaining appliance |
DE2527706A1 (en) | 1975-06-21 | 1976-12-30 | Hanfried Dr Med Weigand | DEVICE FOR THE INTRODUCTION OF CONTRAST AGENTS INTO AN ARTIFICIAL INTESTINAL OUTLET |
DE2640413C3 (en) | 1976-09-08 | 1980-03-27 | Richard Wolf Gmbh, 7134 Knittlingen | Catheter monitor |
NL7710909A (en) | 1976-10-08 | 1978-04-11 | Smith & Nephew | COMPOSITE STRAPS. |
GB1562244A (en) | 1976-11-11 | 1980-03-05 | Lock P M | Wound dressing materials |
US4080970A (en) | 1976-11-17 | 1978-03-28 | Miller Thomas J | Post-operative combination dressing and internal drain tube with external shield and tube connector |
US4139004A (en) | 1977-02-17 | 1979-02-13 | Gonzalez Jr Harry | Bandage apparatus for treating burns |
US4184510A (en) | 1977-03-15 | 1980-01-22 | Fibra-Sonics, Inc. | Valued device for controlling vacuum in surgery |
US4165748A (en) | 1977-11-07 | 1979-08-28 | Johnson Melissa C | Catheter tube holder |
US4256109A (en) | 1978-07-10 | 1981-03-17 | Nichols Robert L | Shut off valve for medical suction apparatus |
SE414994B (en) | 1978-11-28 | 1980-09-01 | Landstingens Inkopscentral | VENKATETERFORBAND |
GB2047543B (en) | 1978-12-06 | 1983-04-20 | Svedman Paul | Device for treating tissues for example skin |
US4266545A (en) | 1979-04-06 | 1981-05-12 | Moss James P | Portable suction device for collecting fluids from a closed wound |
US4284079A (en) | 1979-06-28 | 1981-08-18 | Adair Edwin Lloyd | Method for applying a male incontinence device |
US4261363A (en) | 1979-11-09 | 1981-04-14 | C. R. Bard, Inc. | Retention clips for body fluid drains |
US4569348A (en) | 1980-02-22 | 1986-02-11 | Velcro Usa Inc. | Catheter tube holder strap |
EP0035583B1 (en) | 1980-03-11 | 1985-08-14 | Schmid, Eduard, Dr.Dr.med. | Skin graft pressure bandage |
US4297995A (en) | 1980-06-03 | 1981-11-03 | Key Pharmaceuticals, Inc. | Bandage containing attachment post |
US4333468A (en) | 1980-08-18 | 1982-06-08 | Geist Robert W | Mesentery tube holder apparatus |
US4465485A (en) | 1981-03-06 | 1984-08-14 | Becton, Dickinson And Company | Suction canister with unitary shut-off valve and filter features |
US4392853A (en) | 1981-03-16 | 1983-07-12 | Rudolph Muto | Sterile assembly for protecting and fastening an indwelling device |
US4373519A (en) | 1981-06-26 | 1983-02-15 | Minnesota Mining And Manufacturing Company | Composite wound dressing |
US4392858A (en) | 1981-07-16 | 1983-07-12 | Sherwood Medical Company | Wound drainage device |
US4419097A (en) | 1981-07-31 | 1983-12-06 | Rexar Industries, Inc. | Attachment for catheter tube |
AU550575B2 (en) | 1981-08-07 | 1986-03-27 | Richard Christian Wright | Wound drainage device |
SE429197B (en) | 1981-10-14 | 1983-08-22 | Frese Nielsen | SAR TREATMENT DEVICE |
DE3146266A1 (en) | 1981-11-21 | 1983-06-01 | B. Braun Melsungen Ag, 3508 Melsungen | COMBINED DEVICE FOR A MEDICAL SUCTION DRAINAGE |
US4551139A (en) | 1982-02-08 | 1985-11-05 | Marion Laboratories, Inc. | Method and apparatus for burn wound treatment |
US4475909A (en) | 1982-05-06 | 1984-10-09 | Eisenberg Melvin I | Male urinary device and method for applying the device |
DE3361779D1 (en) | 1982-07-06 | 1986-02-20 | Dow Corning | Medical-surgical dressing and a process for the production thereof |
NZ206837A (en) | 1983-01-27 | 1986-08-08 | Johnson & Johnson Prod Inc | Thin film adhesive dressing:backing material in three sections |
US4548202A (en) | 1983-06-20 | 1985-10-22 | Ethicon, Inc. | Mesh tissue fasteners |
US4540412A (en) | 1983-07-14 | 1985-09-10 | The Kendall Company | Device for moist heat therapy |
US4543100A (en) | 1983-11-01 | 1985-09-24 | Brodsky Stuart A | Catheter and drain tube retainer |
US4525374A (en) | 1984-02-27 | 1985-06-25 | Manresa, Inc. | Treating hydrophobic filters to render them hydrophilic |
GB2157958A (en) | 1984-05-03 | 1985-11-06 | Ernest Edward Austen Bedding | Ball game net support |
US4897081A (en) | 1984-05-25 | 1990-01-30 | Thermedics Inc. | Percutaneous access device |
US5215522A (en) | 1984-07-23 | 1993-06-01 | Ballard Medical Products | Single use medical aspirating device and method |
GB8419745D0 (en) | 1984-08-02 | 1984-09-05 | Smith & Nephew Ass | Wound dressing |
US4872450A (en) | 1984-08-17 | 1989-10-10 | Austad Eric D | Wound dressing and method of forming same |
US4655754A (en) | 1984-11-09 | 1987-04-07 | Stryker Corporation | Vacuum wound drainage system and lipids baffle therefor |
US4826494A (en) | 1984-11-09 | 1989-05-02 | Stryker Corporation | Vacuum wound drainage system |
US4605399A (en) | 1984-12-04 | 1986-08-12 | Complex, Inc. | Transdermal infusion device |
US5037397A (en) | 1985-05-03 | 1991-08-06 | Medical Distributors, Inc. | Universal clamp |
US4640688A (en) | 1985-08-23 | 1987-02-03 | Mentor Corporation | Urine collection catheter |
JPS6257646A (en) * | 1985-09-09 | 1987-03-13 | Fuji Photo Film Co Ltd | Microcapsule having silyl ether bond |
US4766037A (en) * | 1985-09-09 | 1988-08-23 | Fuji Photo Film Co., Ltd. | Photodegradable microcapsules |
US4710165A (en) | 1985-09-16 | 1987-12-01 | Mcneil Charles B | Wearable, variable rate suction/collection device |
US4758220A (en) | 1985-09-26 | 1988-07-19 | Alcon Laboratories, Inc. | Surgical cassette proximity sensing and latching apparatus |
US4733659A (en) | 1986-01-17 | 1988-03-29 | Seton Company | Foam bandage |
EP0256060A1 (en) | 1986-01-31 | 1988-02-24 | OSMOND, Roger L. W. | Suction system for wound and gastro-intestinal drainage |
US4838883A (en) | 1986-03-07 | 1989-06-13 | Nissho Corporation | Urine-collecting device |
JPS62281965A (en) | 1986-05-29 | 1987-12-07 | テルモ株式会社 | Catheter and catheter fixing member |
GB8621884D0 (en) | 1986-09-11 | 1986-10-15 | Bard Ltd | Catheter applicator |
GB2195255B (en) | 1986-09-30 | 1991-05-01 | Vacutec Uk Limited | Apparatus for vacuum treatment of an epidermal surface |
US4743232A (en) | 1986-10-06 | 1988-05-10 | The Clinipad Corporation | Package assembly for plastic film bandage |
DE3634569A1 (en) | 1986-10-10 | 1988-04-21 | Sachse Hans E | CONDOM CATHETER, A URINE TUBE CATHETER FOR PREVENTING RISING INFECTIONS |
JPS63135179A (en) | 1986-11-26 | 1988-06-07 | 立花 俊郎 | Subcataneous drug administration set |
GB8628564D0 (en) | 1986-11-28 | 1987-01-07 | Smiths Industries Plc | Anti-foaming agent suction apparatus |
GB8706116D0 (en) | 1987-03-14 | 1987-04-15 | Smith & Nephew Ass | Adhesive dressings |
US4787888A (en) | 1987-06-01 | 1988-11-29 | University Of Connecticut | Disposable piezoelectric polymer bandage for percutaneous delivery of drugs and method for such percutaneous delivery (a) |
US4863449A (en) | 1987-07-06 | 1989-09-05 | Hollister Incorporated | Adhesive-lined elastic condom cathether |
US5176663A (en) | 1987-12-02 | 1993-01-05 | Pal Svedman | Dressing having pad with compressibility limiting elements |
US4906240A (en) | 1988-02-01 | 1990-03-06 | Matrix Medica, Inc. | Adhesive-faced porous absorbent sheet and method of making same |
US4985019A (en) | 1988-03-11 | 1991-01-15 | Michelson Gary K | X-ray marker |
GB8812803D0 (en) | 1988-05-28 | 1988-06-29 | Smiths Industries Plc | Medico-surgical containers |
US4919654A (en) | 1988-08-03 | 1990-04-24 | Kalt Medical Corporation | IV clamp with membrane |
US5000741A (en) | 1988-08-22 | 1991-03-19 | Kalt Medical Corporation | Transparent tracheostomy tube dressing |
US5059596A (en) | 1989-01-16 | 1991-10-22 | Roussel Uclaf | Azabicyclo compounds |
GB8906100D0 (en) | 1989-03-16 | 1989-04-26 | Smith & Nephew | Laminates |
US5261893A (en) | 1989-04-03 | 1993-11-16 | Zamierowski David S | Fastening system and method |
US5527293A (en) | 1989-04-03 | 1996-06-18 | Kinetic Concepts, Inc. | Fastening system and method |
US4969880A (en) | 1989-04-03 | 1990-11-13 | Zamierowski David S | Wound dressing and treatment method |
US5100396A (en) | 1989-04-03 | 1992-03-31 | Zamierowski David S | Fluidic connection system and method |
US5358494A (en) | 1989-07-11 | 1994-10-25 | Svedman Paul | Irrigation dressing |
JP2719671B2 (en) | 1989-07-11 | 1998-02-25 | 日本ゼオン株式会社 | Wound dressing |
US5232453A (en) | 1989-07-14 | 1993-08-03 | E. R. Squibb & Sons, Inc. | Catheter holder |
GB2235877A (en) | 1989-09-18 | 1991-03-20 | Antonio Talluri | Closed wound suction apparatus |
US5134994A (en) | 1990-02-12 | 1992-08-04 | Say Sam L | Field aspirator in a soft pack with externally mounted container |
US5092858A (en) | 1990-03-20 | 1992-03-03 | Becton, Dickinson And Company | Liquid gelling agent distributor device |
JP2941918B2 (en) | 1990-09-19 | 1999-08-30 | テルモ株式会社 | Weighing device |
US5149331A (en) | 1991-05-03 | 1992-09-22 | Ariel Ferdman | Method and device for wound closure |
US5278100A (en) | 1991-11-08 | 1994-01-11 | Micron Technology, Inc. | Chemical vapor deposition technique for depositing titanium silicide on semiconductor wafers |
US5645081A (en) | 1991-11-14 | 1997-07-08 | Wake Forest University | Method of treating tissue damage and apparatus for same |
US5636643A (en) | 1991-11-14 | 1997-06-10 | Wake Forest University | Wound treatment employing reduced pressure |
US5279550A (en) | 1991-12-19 | 1994-01-18 | Gish Biomedical, Inc. | Orthopedic autotransfusion system |
US5167613A (en) | 1992-03-23 | 1992-12-01 | The Kendall Company | Composite vented wound dressing |
FR2690617B1 (en) | 1992-04-29 | 1994-06-24 | Cbh Textile | TRANSPARENT ADHESIVE DRESSING. |
DE4306478A1 (en) | 1993-03-02 | 1994-09-08 | Wolfgang Dr Wagner | Drainage device, in particular pleural drainage device, and drainage method |
US6241747B1 (en) | 1993-05-03 | 2001-06-05 | Quill Medical, Inc. | Barbed Bodily tissue connector |
US5342376A (en) | 1993-05-03 | 1994-08-30 | Dermagraphics, Inc. | Inserting device for a barbed tissue connector |
US5344415A (en) | 1993-06-15 | 1994-09-06 | Deroyal Industries, Inc. | Sterile system for dressing vascular access site |
US5437651A (en) | 1993-09-01 | 1995-08-01 | Research Medical, Inc. | Medical suction apparatus |
US5466465A (en) † | 1993-12-30 | 1995-11-14 | Harrogate Holdings, Limited | Transdermal drug delivery system |
US5549584A (en) | 1994-02-14 | 1996-08-27 | The Kendall Company | Apparatus for removing fluid from a wound |
WO1997004836A1 (en) | 1994-03-21 | 1997-02-13 | Dusa Pharmaceuticals, Inc. | Patch, controller, and method for the photodynamic therapy of a dermal lesion |
US5474528A (en) * | 1994-03-21 | 1995-12-12 | Dusa Pharmaceuticals, Inc. | Combination controller and patch for the photodynamic therapy of dermal lesion |
US5556375A (en) | 1994-06-16 | 1996-09-17 | Hercules Incorporated | Wound dressing having a fenestrated base layer |
US5607388A (en) | 1994-06-16 | 1997-03-04 | Hercules Incorporated | Multi-purpose wound dressing |
US5664270A (en) | 1994-07-19 | 1997-09-09 | Kinetic Concepts, Inc. | Patient interface system |
DE69528716T2 (en) | 1994-08-22 | 2003-03-20 | Kinetic Concepts Inc | Canister for wound drainage |
DE29504378U1 (en) | 1995-03-15 | 1995-09-14 | MTG Medizinisch, technische Gerätebau GmbH, 66299 Friedrichsthal | Electronically controlled low-vacuum pump for chest and wound drainage |
GB9523253D0 (en) | 1995-11-14 | 1996-01-17 | Mediscus Prod Ltd | Portable wound treatment apparatus |
US6135116A (en) | 1997-07-28 | 2000-10-24 | Kci Licensing, Inc. | Therapeutic method for treating ulcers |
AU755496B2 (en) | 1997-09-12 | 2002-12-12 | Kci Licensing, Inc. | Surgical drape and suction head for wound treatment |
GB9719520D0 (en) | 1997-09-12 | 1997-11-19 | Kci Medical Ltd | Surgical drape and suction heads for wound treatment |
US6071267A (en) | 1998-02-06 | 2000-06-06 | Kinetic Concepts, Inc. | Medical patient fluid management interface system and method |
US6488643B1 (en) | 1998-10-08 | 2002-12-03 | Kci Licensing, Inc. | Wound healing foot wrap |
US6287316B1 (en) | 1999-03-26 | 2001-09-11 | Ethicon, Inc. | Knitted surgical mesh |
US7799004B2 (en) | 2001-03-05 | 2010-09-21 | Kci Licensing, Inc. | Negative pressure wound treatment apparatus and infection identification system and method |
US6856821B2 (en) | 2000-05-26 | 2005-02-15 | Kci Licensing, Inc. | System for combined transcutaneous blood gas monitoring and vacuum assisted wound closure |
US6991643B2 (en) | 2000-12-20 | 2006-01-31 | Usgi Medical Inc. | Multi-barbed device for retaining tissue in apposition and methods of use |
ES2220734T3 (en) | 2000-02-24 | 2004-12-16 | Venetec International, Inc. | UNIVERSAL FIXING SYSTEM FOR CATETER. |
US6540705B2 (en) | 2001-02-22 | 2003-04-01 | Core Products International, Inc. | Ankle brace providing upper and lower ankle adjustment |
CA2552690C (en) | 2002-12-31 | 2014-12-09 | Ultra-Sonic Technologies, L.L.C. | Transdermal delivery using encapsulated agent activated by ultrasound and/or heat |
US7976519B2 (en) | 2002-12-31 | 2011-07-12 | Kci Licensing, Inc. | Externally-applied patient interface system and method |
US8153591B2 (en) * | 2003-08-26 | 2012-04-10 | Gel-Del Technologies, Inc. | Protein biomaterials and biocoacervates and methods of making and using thereof |
GB0409443D0 (en) * | 2004-04-28 | 2004-06-02 | Smith & Nephew | Apparatus |
GB0325120D0 (en) † | 2003-10-28 | 2003-12-03 | Smith & Nephew | Apparatus with actives |
GB0325126D0 (en) | 2003-10-28 | 2003-12-03 | Smith & Nephew | Apparatus with heat |
US7753894B2 (en) | 2004-04-27 | 2010-07-13 | Smith & Nephew Plc | Wound cleansing apparatus with stress |
GB0508528D0 (en) * | 2005-04-27 | 2005-06-01 | Smith & Nephew | SAI with macrostress |
GB0409444D0 (en) * | 2004-04-28 | 2004-06-02 | Smith & Nephew | Apparatus |
GB0508531D0 (en) * | 2005-04-27 | 2005-06-01 | Smith & Nephew | Sai with ultrasound |
US20060173514A1 (en) * | 2005-02-02 | 2006-08-03 | Advanced Photodynamic Technologies, Inc. | Wound treatment device for photodynamic therapy and method of using same |
US7503910B2 (en) | 2006-02-01 | 2009-03-17 | Carmeli Adahan | Suctioning system, method and kit |
DK2010245T3 (en) | 2005-11-21 | 2016-01-18 | Joshua David Smith | WOUND CARE SYSTEM |
US20070258903A1 (en) * | 2006-05-02 | 2007-11-08 | Kleiner Lothar W | Methods, compositions and devices for treating lesioned sites using bioabsorbable carriers |
US20070299369A1 (en) † | 2006-06-26 | 2007-12-27 | Eilaz Babaev | Ultrasound wound care device and method |
WO2008130689A1 (en) | 2007-04-20 | 2008-10-30 | Eran Eilat | Device and method for treating chronic wounds |
CN101925369A (en) * | 2008-02-27 | 2010-12-22 | 凯希特许有限公司 | System and method for healing wound at tissue site |
CA2722671A1 (en) | 2008-04-30 | 2009-11-05 | Amy Mcnulty | Use of nucleic acids with reduced pressure therapy |
US20100055158A1 (en) * | 2008-08-28 | 2010-03-04 | Tyco Healthcare Group Lp | Environmentally Activated Compositions, Articles and Methods |
US20110015587A1 (en) | 2009-07-14 | 2011-01-20 | Tumey David M | Irrigation Device and Method Using Same |
WO2012009613A1 (en) * | 2010-07-16 | 2012-01-19 | Seventh Sense Biosystems, Inc. | Low-pressure environment for fluid transfer devices |
CN107033596A (en) * | 2010-11-25 | 2017-08-11 | 史密夫及内修公开有限公司 | Composition I-II and products thereof and purposes |
US8944067B2 (en) * | 2010-12-15 | 2015-02-03 | Kci Licensing, Inc. | Targeted delivery of magnetically tagged active agents in combination with negative pressure wound therapy |
US8708981B2 (en) * | 2011-05-26 | 2014-04-29 | Kci Licensing, Inc. | Systems and methods of stimulation and activation of fluids for use with instillation therapy |
-
2012
- 2012-05-22 US US13/477,741 patent/US8708981B2/en active Active
- 2012-05-22 EP EP12724062.0A patent/EP2714117B2/en active Active
- 2012-05-22 CN CN201610847233.4A patent/CN106176046A/en active Pending
- 2012-05-22 WO PCT/US2012/038932 patent/WO2012162287A1/en active Application Filing
- 2012-05-22 CN CN201280022323.XA patent/CN103517722B/en active Active
- 2012-05-22 JP JP2014512940A patent/JP6449015B2/en active Active
- 2012-05-22 AU AU2012258916A patent/AU2012258916B2/en not_active Ceased
- 2012-05-22 CA CA2834702A patent/CA2834702C/en not_active Expired - Fee Related
-
2014
- 2014-03-17 US US14/216,522 patent/US9623224B2/en active Active
-
2016
- 2016-09-15 AU AU2016228240A patent/AU2016228240B2/en active Active
-
2017
- 2017-03-13 US US15/456,886 patent/US10406337B2/en active Active
-
2019
- 2019-07-22 US US16/517,788 patent/US20190336739A1/en not_active Abandoned
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11628093B2 (en) | 2008-05-08 | 2023-04-18 | Convatec Technologies, Inc. | Wound dressing |
US11458044B2 (en) | 2008-09-29 | 2022-10-04 | Convatec Technologies Inc. | Wound dressing |
US11135315B2 (en) | 2010-11-30 | 2021-10-05 | Convatec Technologies Inc. | Composition for detecting biofilms on viable tissues |
US11116884B2 (en) | 2010-12-08 | 2021-09-14 | Convatec Technologies Inc. | Integrated system for assessing wound exudates |
US11241525B2 (en) | 2010-12-08 | 2022-02-08 | Convatec Technologies Inc. | Wound exudate monitor accessory |
US11583430B2 (en) | 2011-09-02 | 2023-02-21 | Convatec Ltd. | Skin contact material |
US11241339B2 (en) | 2011-11-29 | 2022-02-08 | Convatec Inc. | Perforated binder for laminated wound dressing |
US10968543B2 (en) | 2011-12-01 | 2021-04-06 | Convatec Technologies Inc. | Wound dressing for use in vacuum therapy |
US11286601B2 (en) | 2012-12-20 | 2022-03-29 | Convatec Technologies, Inc. | Processing of chemically modified cellulosic fibres |
US11740241B2 (en) | 2016-03-30 | 2023-08-29 | Synovo Gmbh | Construct including an anchor, an enzyme recognition site and an indicator region for detecting microbial infection in wounds |
US11723808B2 (en) | 2016-03-30 | 2023-08-15 | Convatec Technologies Inc. | Detecting microbial infections in wounds |
US11596554B2 (en) | 2016-07-08 | 2023-03-07 | Convatec Technologies Inc. | Flexible negative pressure system |
US11452808B2 (en) | 2016-07-08 | 2022-09-27 | Convatec Technologies Inc. | Fluid flow sensing |
US11266774B2 (en) | 2016-07-08 | 2022-03-08 | Convatec Technologies Inc. | Fluid collection apparatus |
US20220031519A1 (en) * | 2018-11-29 | 2022-02-03 | Nexa Medical Limited | Wound-Dressing Conditioning Device |
US11331221B2 (en) | 2019-12-27 | 2022-05-17 | Convatec Limited | Negative pressure wound dressing |
US11771819B2 (en) | 2019-12-27 | 2023-10-03 | Convatec Limited | Low profile filter devices suitable for use in negative pressure wound therapy systems |
Also Published As
Publication number | Publication date |
---|---|
AU2016228240A1 (en) | 2016-10-06 |
EP2714117B1 (en) | 2016-01-06 |
US8708981B2 (en) | 2014-04-29 |
CA2834702C (en) | 2019-03-26 |
EP2714117B2 (en) | 2018-10-24 |
AU2012258916B2 (en) | 2016-06-16 |
US9623224B2 (en) | 2017-04-18 |
CN106176046A (en) | 2016-12-07 |
JP6449015B2 (en) | 2019-01-09 |
US20170239096A1 (en) | 2017-08-24 |
AU2012258916A1 (en) | 2013-10-31 |
AU2016228240B2 (en) | 2018-07-19 |
US20140200526A1 (en) | 2014-07-17 |
CN103517722A (en) | 2014-01-15 |
CA2834702A1 (en) | 2012-11-29 |
EP2714117A1 (en) | 2014-04-09 |
CN103517722B (en) | 2016-10-19 |
US10406337B2 (en) | 2019-09-10 |
JP2014519380A (en) | 2014-08-14 |
WO2012162287A1 (en) | 2012-11-29 |
US20120302973A1 (en) | 2012-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10406337B2 (en) | Systems and methods of stimulation and activation of fluids for use with instillation therapy | |
US10092452B2 (en) | Targeted delivery of magnetically tagged active agents in combination with negative pressure wound therapy | |
US20210128362A1 (en) | Devices, systems, and methods for instillation of foamed fluid with negative pressure wound therapy | |
US20210128802A1 (en) | Leak-resistant bandage systems and methods with hydrophilic foam wound insert for fluid-instillation and/or negative-pressure wound therapies | |
US10506928B2 (en) | Systems, devices, and methods for identifying portions of a wound filler left at a tissue site | |
US8785713B2 (en) | Compositions with reactive ingredients, and wound dressings, apparatuses, and methods | |
CN101360473B (en) | System for treating a wound using ultrasonic debribement | |
US20050186260A1 (en) | Medicated gel foam and method of use | |
TWM498591U (en) | Negative pressure wound dressing | |
Rotering et al. | Preliminary Results of a New Treatment Strategy for Relapsed Left Ventricular Assist Device–Specific Infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: KCI LICENSING, INC., TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LOCKE, CHRISTOPHER;ROBINSON, TIM;COULTHARD, RICHARD;REEL/FRAME:052284/0918 Effective date: 20120508 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |